Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01790243 · ClinicalTrials.gov registry record · NA
LEVANT 2 Safety Registry
A NA study, sponsored by C. R. Bard.
- Completed
- Registry status
- NA
- Development phase
- 1,189
- Enrollment target
NCT01790243 is a NA study that has completed, run by C. R. Bard. The registered enrollment target is 1,189 participants.
The verdict
NCT01790243, a NA study, has completed, sponsored by C. R. Bard.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,189 participants
- Enrollment target
Study Summary
The primary objective of the LEVANT 2 Extended Follow-up Post-Approval Study (PAS 1) is to evaluate the long-term performance of the Lutonix Drug Coated Balloon (DCB) versus Percutaneous Transluminal Balloon Angioplasty (PTA) in the treatment of stenosis or occlusion of the femoropopliteal arteries.
Interventions
- DEVICE Lutonix Drug Coated Balloon
- DEVICE Standard PTA Balloon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,189 participants |
| Start Date | 2011-07-20 |
| Est. Completion | 2018-11-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01790243
The ClinicalTrials.gov registry entry for NCT01790243 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 1,189 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is C. R. Bard, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lutonix Drug Coated Balloon is the first listed.
NCT01790243 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01790243 about?
NCT01790243 is a clinical study titled "LEVANT 2 Safety Registry". The primary objective of the LEVANT 2 Extended Follow-up Post-Approval Study (PAS 1) is to evaluate the long-term performance of the Lutonix Drug Coated Balloon (DCB) versus Percutaneous Transluminal Balloon Angioplasty (PTA) in the treatment of stenosis or occlusion of the femoropopliteal arteries.
What is the current status of trial NCT01790243?
This trial is currently completed. It is a NA study. The enrollment target is 1,189 participants. The study started on 2011-07-20. Estimated completion is 2018-11-01.
What interventions are being tested in trial NCT01790243?
The interventions under investigation include: Lutonix Drug Coated Balloon (DEVICE), Standard PTA Balloon (DEVICE).
Who is sponsoring clinical trial NCT01790243?
This trial is sponsored by C. R. Bard, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.